Metformin use linked to lower death risk and better inflammation markers in U.S. adults with diabetes

People with Type 2 diabetes often take metformin to manage their blood sugar. But doctors have long wondered if this common drug does more than just control glucose levels. A large review of data from U.S. adults found that those using metformin showed signs of lower inflammation and a reduced risk of dying from any cause or heart disease compared to non-users. This analysis looked at over 2,100 adults who reported having diabetes between 2013 and 2018. The researchers tracked these individuals through 2019 to see who survived and who did not. They also measured specific blood markers that signal how the body handles stress and infection. The results showed that metformin users had lower levels of neutrophil-to-lymphocyte ratio and monocyte-to-lymphocyte ratio. These are numbers that help scientists understand how the immune system is working. Users also had higher levels of serum albumin, a protein that helps keep fluid in the blood vessels. The link to lower death risk was clear, but the connection to heart disease specifically was less certain in this group. The study did not report any safety issues or side effects for the people in this specific dataset. However, the researchers noted that this evidence comes from a broad survey of the population rather than a tightly controlled trial. This means the findings show a strong connection but do not prove that the drug directly causes these benefits. The data suggests that metformin might work through pathways that reduce inflammation, which could explain its long-known benefits. More research is needed to confirm these links and to understand exactly how the drug helps people live longer and healthier lives.